TARSONS · Tarsons Products Ltd · Scientific & Technical Instr.
TARSONS · Tarsons Products Ltd · Scientific & Technical Instr.
As of 05 Nov close
52-week range
15.1% below 52-week high
52-week range: as of 05 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 52 days old
Revenue (latest Q)
₹110 Cr
Revenue YoY
PAT YoY
-180.9%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
2.8
P/S (TTM)
3.8
Sector P/E
42
Dividend yield
0.0%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| TARSONS (this stock) | 128.8 | 2.8 | +2.5% | +1.8% | 0.62 | 0.0% |
| Shivalik Bimetal Controls | 44 | 8.8 | +16.8% | +21.6% | 4.66 | +0.5% |
| Rishabh Instruments | 27.2 | 4.4 | +10.3% | +10.8% | 0.11 | +0.2% |
| Rolcon Engineering Company | 12.5 | 1.4 | +6.4% | +11.9% | 0.18 | +0.5% |
Promoter
stable
FII
falling 3q
MF
0.05% (+0.01pp)
stable
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
| canonicalSymbol | date | buy quantity | buyer count | deal strength | deal types present |
|---|---|---|---|---|---|
| TARSONS | 2026-08-14 | 984154 | 3 | WEAK | BULK |
| TARSONS | 2026-07-21 | 350036 | 1 | WEAK | BULK |
| TARSONS | 2026-07-06 | 686441 | 2 | WEAK | BULK |
| TARSONS | 2026-06-17 | 5352240 | 9 | WEAK | BULK |
News timeline
No related news.
Concalls & investor presentations
AI-generatedKey takeaway: Tarsons Products Limited reported a consolidated revenue of Rs. 110 crores for Q1 FY’27, reflecting a year-on-year growth of nearly 21%. Standalone revenue also grew by 21% to Rs. 86 crores, marking the highest Q1 standalone revenue in the company's history. Domestic sales increased by 17% year-on-year, supported by a robust distribution network and improved demand conditions. The company noted a significant recovery in customer inquiries and order pipelines, particularly in the export segment, which grew by 29%. However, margins were impacted by rising raw material costs, with EBITDA margins affected by operational expenses from new facilities. Management indicated that profitability remains under pressure due to higher depreciation and interest costs but highlighted an 18% year-on-year increase in cash profit. The company is focused on leveraging its expanded capacities and product portfolio to drive future growth, particularly in the domestic and international markets.
The document presented both positive growth metrics and challenges related to margins and costs.
Sourced from an exchange-filed transcript, dated 17 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Tarsons Products Limited reported a consolidated revenue of ₹110.2 crores for Q1 FY27, reflecting a 21% year-on-year growth, driven by strong performance across product categories and geographies. The domestic business achieved a 17% growth, while export revenues surged by 29% year-on-year, indicating a recovery from previous geopolitical challenges. However, the company noted that margins were impacted by rising raw material costs and expenses related to new facilities in Amta and Panchla. The presentation highlighted a negative profit after tax of ₹1.4 crores for the quarter, attributed to accelerated depreciation and higher finance costs, although cash profit after tax grew by 18% year-on-year to ₹25 crores. Management expressed optimism about future growth, citing ongoing customer inquiries and the potential of new product lines. The company emphasized its commitment to long-term growth and capacity expansion in the labware market.
The document presented both positive revenue growth and challenges related to margins and profitability.
Sourced from an exchange-filed presentation, dated 11 Aug 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Tarsons Products Limited reported its highest quarterly revenue of INR 121 crores for Q4 FY'26, marking a year-on-year growth of 7.4%. For the full fiscal year, revenue reached INR 426 crores, reflecting a 7.7% increase. The domestic business showed strong performance with an 11.7% growth, while export revenue declined by 13.4% due to geopolitical tensions affecting global supply chains. Management noted that gross and EBITDA margins were impacted by rising raw material costs and operational expenses from new facilities. Despite these challenges, cash PAT for FY'26 increased by 21.5% to INR 112 crores. Management expressed confidence in the company's long-term growth potential, supported by recent capacity expansions and a diversified product portfolio. They highlighted ongoing efforts to monitor supply chain issues and adapt pricing strategies in response to raw material cost fluctuations.
The document presented both positive revenue growth and challenges related to margins and exports.
Sourced from an exchange-filed transcript, dated 01 Jun 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Tarsons Products Limited reported its financial results for the quarter and financial year ended March 31, 2026, highlighting a consolidated revenue of ₹422.5 crores, reflecting an 8% growth over the previous year. The management noted a decline in profit after tax (PAT) primarily due to increased depreciation and finance costs associated with new facilities, with cash PAT showing a strong growth of 21% year-on-year. The domestic business experienced a healthy 12% growth in Q4FY26, while export revenues faced challenges due to geopolitical issues affecting transit times. The management emphasized the company's commitment to long-term growth, supported by new capacities and an expanded product portfolio. The presentation also detailed the company's operational highlights, including a focus on automation and efficiency improvements in manufacturing processes, and plans for further expansion in both domestic and international markets.
The management highlighted both growth in revenue and challenges impacting profitability.
Sourced from an exchange-filed presentation, dated 23 May 2026. Summary is RedixFi-generated and distinct from investment advice.
Key takeaway: Tarsons Products Limited submitted an investor presentation for the quarter and nine months ended December 31, 2025. The presentation highlighted that consolidated revenue for Q3FY26 was ₹107.9 crores, reflecting a year-on-year growth of 12.8%. EBITDA increased by 6.3% to ₹31.5 crores, while the adjusted profit after tax (PAT) rose by 21.4% to ₹6.4 crores. The company reported a decline in PAT primarily due to accelerated depreciation and higher finance costs from new facilities. Management noted that cash PAT for the nine months of FY26 grew by 27.3%. The presentation also emphasized ongoing capacity expansion and the introduction of new product lines, positioning the company for future growth. Tarsons highlighted its strong market presence and commitment to enhancing manufacturing capabilities and expanding its product portfolio.
Management emphasized growth and ongoing capacity expansion initiatives.
Sourced from an exchange-filed presentation, dated 06 Feb 2026. Summary is RedixFi-generated and distinct from investment advice.
AI Summary of Annual Report
AI-generatedTarsons Products Limited, a life sciences company specializing in laboratory products, emphasizes precision, quality, and disciplined execution in its operations. The report highlights the company's focus on expanding manufacturing capacity through automation and cleanroom environments, with expansions at Panchla and Amta aimed at enhancing production while maintaining quality control. Strategic priorities include diversifying product offerings into cell culture and robotic-handled consumables, leveraging the 'Make in India' initiative, and strengthening brand visibility. The company also underscores its commitment to corporate governance, sustainability, and risk management frameworks.
- Expansion of manufacturing capacity through automation and cleanroom environments at Panchla and Amta facilities.
- Diversification into cell culture and robotic-handled consumables to target underserved markets.
- Leveraging 'Make in India' to boost domestic sales while maintaining export focus.
- Strengthening brand visibility through intensified branding and promotional efforts.
- Management has stated a target of enhancing production while maintaining quality control.
Key takeaway: Tarsons Products Limited is focused on expanding its manufacturing capabilities and product portfolio while maintaining precision and quality, supported by strategic investments in automation and cleanroom environments.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
Default / Covenant Breach (2 items); Investigation or enforcement mention (1 item)
Items of these kinds are disclosed in the filings. This is a count of disclosed items. It is not a finding about the company and its cause has not been independently established.
Default / Covenant Breach
2 occurrencesRecent (last 12 months)
The Holding Company has not filed quarterly returns or statements with banks for the quarter ended 31st March, 2025, and there are discrepancies between the amounts disclosed in quarterly returns/statements and the unaudited books of account.
Earlier (1-3 years ago)
The company has substantial defaults in payment to depositors, debenture holders, shareholders (in case of non-payment of declared dividends) and creditors.
Investigation or enforcement mention
1 occurrenceRecent (last 12 months)
The company paid excess managerial remuneration amounting to INR 41.39 million to its directors, which exceeded the limits set by Section 197 of the Companies Act, 2013. The company seeks shareholder approval to waive this excess remuneration.
Routine disclosures
Contingent Liability
2 occurrencesRecent (last 12 months)
The company has contingent liabilities related to disputed Goods and Service Tax and Custom Duty claims. Additionally, it has a corporate financial guarantee of Euro 10.6 million for a subsidiary's loan from Citi Bank N.A., Singapore.
Earlier (1-3 years ago)
The company has contingent liabilities related to disputed Goods & Service Tax claims as of 31st March, 2024. The company cannot estimate the timing of cash outflows for these liabilities and does not expect any reimbursements.
Related-Party Transaction
2 occurrencesRecent (last 12 months)
The company has a related party transaction involving Tarsons Life Science Pte. Ltd., including deemed investment, investment in equity shares, financial guarantee given, corporate guarantee income, interest income on loan given, reimbursement of guarantee commission, repayment of loans given, and reimbursement of expenses.
Earlier (1-3 years ago)
The company will consider and approve a Material Related Party Transaction at its AGM.
Management & Board Governance
1 occurrenceRecent (last 12 months)
Mr. Girish Paman Vanvari, the former Chairperson of the Audit Committee, resigned from the Board effective 6th February 2026, leading to his ceasing as Chairperson of the Audit Committee.